Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201

BACKGROUND: Little is known about the biweekly combined use of cetuximab and chemotherapy as second-line treatment of metastatic colorectal cancer (mCRC). Recently, DNA methylation status has been reported to be a new possible predictor of the efficacy from the anti-epidermal growth factor receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Shin, Ouchi, Kota, Sakamoto, Yasuhiro, Mori, Takahiro, Shimodaira, Hideki, Takahashi, Masahiro, Ohori, Hisatsugu, Kudo, Chieko, Takahashi, Yoshikazu, Imai, Hiroo, Akiyama, Shoko, Takahashi, Masanobu, Suto, Takeshi, Murakawa, Yasuko, Oishi, Takayuki, Isobe, Hideki, Okada, Yoshinari, Kawai, Sadayuki, Yoshioka, Takashi, Sato, Toshihiko, Shindo, Yoshiaki, Sugiyama, Shunsuke, Komine, Keigo, Chiba, Natsuko, Okita, Akira, Yamaguchi, Takuhiro, Ishioka, Chikashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186538/
https://www.ncbi.nlm.nih.gov/pubmed/37201044
http://dx.doi.org/10.21037/jgo-22-862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186538/
https://www.ncbi.nlm.nih.gov/pubmed/37201044
http://dx.doi.org/10.21037/jgo-22-862

Ejemplares similares